{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:04:06Z","timestamp":1789560246924,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":1307,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating inherited skin blistering disease caused by mutations in the COL7A1 gene that encodes type VII collagen (C7), a major structural component of anchoring fibrils at the dermal-epidermal junction (DEJ). We recently demonstrated that human cord blood-derived unrestricted somatic stem cells promote wound healing and ameliorate the blistering phenotype in a RDEB (col7a1\u2212\/\u2212) mouse model. Here, we demonstrate significant therapeutic effect of a further novel stem cell product in RDEB, that is, human placental-derived stem cells (HPDSCs), currently being used as human leukocyte antigen-independent donor cells with allogeneic umbilical cord blood stem cell transplantation in patients with malignant and nonmalignant diseases. HPDSCs are isolated from full-term placentas following saline perfusion, red blood cell depletion, and volume reduction. HPDSCs contain significantly higher level of both hematopoietic and nonhematopoietic stem and progenitor cells than cord blood and are low in T cell content. A single intrahepatic administration of HPDSCs significantly elongated the median life span of the col7a1\u2212\/\u2212 mice from 2 to 7 days and an additional intrahepatic administration significantly extended the median life span to 18 days. We further demonstrated that after intrahepatic administration, HPDSCs engrafted short-term in the organs affected by RDEB, that is, skin and gastrointestinal tract of col7a1\u2212\/\u2212 mice, increased adhesion at the DEJ and deposited C7 even at 4 months after administration of HPDSCs, without inducing anti-C7 antibodies. This study warrants future clinical investigation to determine the safety and efficacy of HPDSCs in patients with severe RDEB.<\/jats:p>","DOI":"10.1002\/sctm.17-0182","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T14:00:25Z","timestamp":1525960825000},"page":"530-542","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model"],"prefix":"10.1093","volume":"7","author":[{"given":"Yanling","family":"Liao","sequence":"first","affiliation":[{"name":"a Department of Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Ivanova","sequence":"additional","affiliation":[{"name":"a Department of Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajarajeswari","family":"Sivalenka","sequence":"additional","affiliation":[{"name":"b Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Plumer","sequence":"additional","affiliation":[{"name":"a Department of Pediatrics, New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen","family":"Zhu","sequence":"additional","affiliation":[{"name":"c Department of Surgery Tianjin Hospital, Tianjin Academy of Integrative Medicine, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Zhang","sequence":"additional","affiliation":[{"name":"b Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Christiano","sequence":"additional","affiliation":[{"name":"d Department of Dermatology Columbia University Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"McGrath","sequence":"additional","affiliation":[{"name":"e St John's Institute of Dermatology, King's College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi P.","family":"Gurney","sequence":"additional","affiliation":[{"name":"b Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[{"name":"a Department of Pediatrics, New York Medical College, Valhalla, New York, USA"},{"name":"f Department of Medicine, New York Medical College, Valhalla, New York, USA"},{"name":"g Department of Pathology, New York Medical College, Valhalla, New York, USA"},{"name":"h Department of Immunology & Microbiology, New York Medical College, Valhalla, New York, USA"},{"name":"i Department of Cell Biology & Anatomy, New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,10]]},"reference":[{"key":"2022022809013826100_sct312317-bib-0001","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ng1193-287","article-title":"A homozygous insertion-deletion in the type VII collagen gene (COL7A1) in Hallopeau-Siemens dystrophic epidermolysis bullosa","volume":"5","author":"Hilal","year":"1993","journal-title":"Nat Genet"},{"key":"2022022809013826100_sct312317-bib-0002","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2022022809013826100_sct312317-bib-0003","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2008.02.004","article-title":"The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB","volume":"58","author":"Fine","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2022022809013826100_sct312317-bib-0004","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1365-2133.2008.08507.x","article-title":"Gastrointestinal complications of epidermolysis bullosa in children","volume":"158","author":"Freeman","year":"2008","journal-title":"Br J Dermatol"},{"key":"2022022809013826100_sct312317-bib-0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpeds.2007.06.039","article-title":"Cause-specific risks of childhood death in inherited epidermolysis bullosa","volume":"152","author":"Fine","year":"2008","journal-title":"J Pediatr"},{"key":"2022022809013826100_sct312317-bib-0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5582\/irdr.2017.01005","article-title":"Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa","volume":"6","author":"Rashidghamat","year":"2017","journal-title":"Intractable Rare Dis Res"},{"key":"2022022809013826100_sct312317-bib-0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjd.14104","article-title":"Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: Best clinical practice guidelines","volume":"174","author":"Mellerio","year":"2016","journal-title":"Br J Dermatol"},{"key":"2022022809013826100_sct312317-bib-0008","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/jid.2013.10","article-title":"Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa","volume":"133","author":"Woodley","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2022022809013826100_sct312317-bib-0009","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/jid.2008.78","article-title":"Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa","volume":"128","author":"Wong","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2022022809013826100_sct312317-bib-0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa","volume":"363","author":"Wagner","year":"2010","journal-title":"N Engl J Med"},{"key":"2022022809013826100_sct312317-bib-0011","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.det.2010.02.004","article-title":"Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa","volume":"28","author":"Kiuru","year":"2010","journal-title":"Dermatol Clin"},{"key":"2022022809013826100_sct312317-bib-0012","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1073\/pnas.1100332108","article-title":"Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells","volume":"108","author":"Itoh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022022809013826100_sct312317-bib-0013","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jid.2016.07.004","article-title":"Stem cell therapy for epidermolysis bullosa-does it work?","volume":"136","author":"Tamai","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2022022809013826100_sct312317-bib-0014","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2022022809013826100_sct312317-bib-0015","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jaad.2013.08.014","article-title":"A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa","volume":"69","author":"Venugopal","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2022022809013826100_sct312317-bib-0016","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/bjd.12599","article-title":"Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: Results of a randomized, vehicle-controlled trial","volume":"169","author":"Petrof","year":"2013","journal-title":"Br J Dermatol"},{"key":"2022022809013826100_sct312317-bib-0017","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood-2008-06-161299","article-title":"Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells","volume":"113","author":"Tolar","year":"2009","journal-title":"Blood"},{"key":"2022022809013826100_sct312317-bib-0018","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jpeds.2015.05.051","article-title":"Reduced toxicity conditioning and allogeneic hematopoietic progenitor cell transplantation for recessive dystrophic epidermolysis bullosa","volume":"167","author":"Geyer","year":"2015","journal-title":"J Pediatr"},{"key":"2022022809013826100_sct312317-bib-0019","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(13)61897-8","article-title":"Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: Repair of the extracellular matrix","volume":"382","author":"Tolar","year":"2013","journal-title":"Lancet"},{"key":"2022022809013826100_sct312317-bib-0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/bmt.2015.196","article-title":"Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients","volume":"51","author":"Cairo","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2022022809013826100_sct312317-bib-0021","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.bbmt.2016.12.236","article-title":"A pilot trial of unrelated donor human placenta-derived stem cells (HPDSC) in conjuction with single unrelated cord blood transplantation (UCBT) in children with malignant and non-malignant disease (IND 14949)","volume":"23","author":"Flower","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809013826100_sct312317-bib-0022","article-title":"Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: A model for recessive dystrophic epidermolysis bullosa","volume":"112","author":"Heinonen","year":"3641","journal-title":"J Cell Sci 1999"},{"key":"2022022809013826100_sct312317-bib-0023","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fimmu.2013.00101","article-title":"Characterization and ex vivo expansion of human placenta-derived natural killer cells for cancer immunotherapy","volume":"4","author":"Kang","year":"2013","journal-title":"Front Immunol"},{"key":"2022022809013826100_sct312317-bib-0024","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3727\/096368913X663569","article-title":"Human cord blood-derived unrestricted somatic stem cells promote wound healing and have therapeutic potential for patients with recessive dystrophic epidermolysis bullosa","volume":"23","author":"Liao","year":"2014","journal-title":"Cell Transplant"},{"key":"2022022809013826100_sct312317-bib-0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa","volume":"17","author":"Remington","year":"2009","journal-title":"Mol Ther"},{"key":"2022022809013826100_sct312317-bib-0026","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/1523-1747.ep12285634","article-title":"Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita","volume":"108","author":"Chen","year":"1997","journal-title":"J Invest Dermatol"},{"key":"2022022809013826100_sct312317-bib-0027","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/stem.1966","article-title":"Rescue of the mucocutaneous manifestations by human cord blood derived nonhematopoietic stem cells in a mouse model of recessive dystrophic epidermolysis bullosa","volume":"33","author":"Liao","year":"2015","journal-title":"Stem Cells"},{"key":"2022022809013826100_sct312317-bib-0028","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1038\/srep11008","article-title":"Systemic high-mobility group box 1 administration suppresses skin inflammation by inducing an accumulation of PDGFRalpha(+) mesenchymal cells from bone marrow","volume":"5","author":"Aikawa","year":"2015","journal-title":"Sci Rep"},{"key":"2022022809013826100_sct312317-bib-0029","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1073\/pnas.1016753108","article-title":"PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia","volume":"108","author":"Tamai","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022022809013826100_sct312317-bib-0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tice.2011.11.004","article-title":"Intrahepatic transplantation of CD34+ cord blood stem cells into newborn and adult NOD\/SCID mice induce differential organ engraftment","volume":"44","author":"Wulf-Goldenberg","year":"2012","journal-title":"Tissue Cell"},{"key":"2022022809013826100_sct312317-bib-0031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/J.JHSB.2004.07.006","article-title":"Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: Experience of the National Epidermolysis Bullosa Registry, 1986\u20132002","volume":"30","author":"Fine","year":"2005","journal-title":"J Hand Surg"},{"key":"2022022809013826100_sct312317-bib-0032","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/jid.2013.137","article-title":"Systemic protein therapy for recessive dystrophic epidermolysis bullosa: How far are we from clinical translation?","volume":"133","author":"Hovnanian","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2022022809013826100_sct312317-bib-0033","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13287-015-0271-2","article-title":"Biodistribution, migration and homing of systemically applied mesenchymal stem\/stromal cells","volume":"7","author":"Leibacher","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"2022022809013826100_sct312317-bib-0034","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1161\/STROKEAHA.115.009854","article-title":"Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke","volume":"46","author":"Acosta","year":"2015","journal-title":"Stroke"},{"key":"2022022809013826100_sct312317-bib-0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.stem.2009.08.020","article-title":"Human placenta is a potent hematopoietic niche containing hematopoietic stem and progenitor cells throughout development","volume":"5","author":"Robin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"2022022809013826100_sct312317-bib-0036","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1933719108327621","article-title":"A new role for the human placenta as a hematopoietic site throughout gestation","volume":"16","author":"Barcena","year":"2009","journal-title":"Reprod Sci"},{"key":"2022022809013826100_sct312317-bib-0037","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ydbio.2008.11.017","article-title":"The human placenta is a hematopoietic organ during the embryonic and fetal periods of development","volume":"327","author":"Barcena","year":"2009","journal-title":"Dev Biol"},{"key":"2022022809013826100_sct312317-bib-0038","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jid.2016.02.002","article-title":"Collagen VII half-life at the dermal-epidermal junction zone: Implications for mechanisms and therapy of genodermatoses","volume":"136","author":"K\u00fchl","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2022022809013826100_sct312317-bib-0039","first-page":"600","article-title":"Skin regenerated from cultured epithelial autografts on full-thickness burn wounds from 6 days to 5 years after grafting. A light, electron microscopic and immunohistochemical study","volume":"60","author":"Compton","year":"1989","journal-title":"Lab Invest"},{"key":"2022022809013826100_sct312317-bib-0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986\u20132006","volume":"60","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2022022809013826100_sct312317-bib-0041","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms","volume":"7","author":"Nystrom","year":"2015","journal-title":"EMBO Mol Med"},{"key":"2022022809013826100_sct312317-bib-0042","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mvr.2009.02.001","article-title":"Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy","volume":"77","author":"Furlani","year":"2009","journal-title":"Microvasc Res"},{"key":"2022022809013826100_sct312317-bib-0043","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","article-title":"Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6","volume":"5","author":"Lee","year":"2009","journal-title":"Cell Stem Cell"},{"key":"2022022809013826100_sct312317-bib-0044","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/dth.12305","article-title":"Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: A randomized controlled trial","volume":"29","author":"El-Darouti","year":"2016","journal-title":"Dermatol Ther"},{"key":"2022022809013826100_sct312317-bib-0045","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2353\/ajpath.2008.070977","article-title":"Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance","volume":"173","author":"Chino","year":"2008","journal-title":"Am J Pathol"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsctm.17-0182","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/7\/7\/530\/42625940\/stcltm_7_7_530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/7\/7\/530\/42625940\/stcltm_7_7_530.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T09:07:39Z","timestamp":1646039259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/7\/7\/530\/6454933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,10]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,5,10]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/sctm.17-0182","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,1]]},"published":{"date-parts":[[2018,5,10]]}}}